February 28, 2025 10:13 AM ESTUpdated 10:47 AM
News Briefing

Paci­ra ab­sorbs GQ Bio for $32M; Lay­offs at BMS, Ei­sai and CRISPR Ther­a­peu­tics

ENDPOINTS

Plus, news about Re­cur­sion, Nx­era, Vi­a­tris and Du­al­i­ty­Bio:

Paci­ra Bio­Sciences takes on GQ Bio: The non-opi­oid pain biotech is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times